Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TARDBP | Q13148 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 1.00 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lipoic Acid, Alpha SCHEMBL51065 | 1.00 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Thioctic Acid SCHEMBL4611014 | 1.00 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL1981737 | 1.00 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Thioctic Acid SCHEMBL7924 | 1.00 | HSD17B10 (1.00) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL25257437 | 0.98 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Thioctic Acid SCHEMBL6037631 | 0.98 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL6037633 | 0.98 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| SCHEMBL7914749 | 0.98 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Thioctic Acid SCHEMBL8948222 | 0.98 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 | |
| Lipoic Acid, Alpha SCHEMBL4898905 | 0.98 | HSD17B10 (0.96) | HSD17B10KMT2ATARDBPCYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608452-A2 | PEPTIDE-ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Eisai R&D Management Co., Ltd. (JP) | 2025-09-03 | — | — | EP | claimed |
| WO-2025082464-A1 | PROTEOLYSIS-TARGETING CHIMERA COMPOUND FOR DEGRADING IRAK4 AND USE THEREOF | 深圳众格生物科技有限公司 | 2025-04-24 | — | — | WO | claimed |
| CN-119780425-A | S-La-based0.3Ni0.7CuO2.5Detection method of zearalanol of polymetallic oxide polyhedron | 山东省东营生态环境监测中心 | 2025-04-08 | — | — | CN | claimed |
| WO-2025036285-A1 | PROTEOLYSIS TARGETING CHIMERA COMPOUND FOR DEGRADING IRAK4 AND USE THEREOF | 深圳众格生物科技有限公司 | 2025-02-20 | — | — | WO | claimed |
| WO-2024109798-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 苏州艾博生物科技有限公司 | 2024-05-30 | — | — | WO | claimed |
| WO-2024092256-A2 | PEPTIDE-ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-02 | — | — | WO | claimed |
| CN-117448393-A | Method for preparing (R) -alpha-lipoic acid by enzyme catalysis | 天驰药业有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-115490667-A | Method for preparing lipoic acid choline ester | 济南明微医药科技有限公司 | 2022-12-20 | — | — | CN | claimed |
| US-20220096467-A1 | COMBINATION OF SELECTIVE ALPHA-ADRENERGIC RECEPTOR AGONIST OR AN ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF | Cellix Bio Provate Limited (IN) | 2022-03-31 | — | — | US | claimed |
| CN-109942426-B | Treatment method for recycling S- (-) -lipoic acid | 福建科宏生物工程股份有限公司 | 2022-03-22 | — | — | CN | claimed |
| EP-2445895-B1 | PIPERAZINE DITHIOCTATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CELLTRION CHEMICAL RES INST (KR) | 2014-02-26 | — | — | EP | claimed |
| US-8541601-B2 | Piperazine dithioctate and pharmaceutical composition comprising the same | CELLTRION CHEMICAL RESEARCH INSTITUTE (KR) | 2013-09-24 | — | — | US | claimed |
| EP-2445895-A2 | PIPERAZINE DITHIOCTATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Celltrion Chemical Research Institute (KR) | 2012-05-02 | — | — | EP | claimed |
| US-20120101107-A1 | PIPERAZINE DITHIOCTATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CELLTRION PHARM, INC. (KR) | 2012-04-26 | — | — | US | claimed |
| WO-2011152658-A2 | PHARMACEUTICAL COMPOSITION COMPRISING PIPERAZINE DITHIOCTATE AND GLIMEPIRIDE | CELLTRION CHEMICAL RESEARCH INSTITUTE (KR) | 2011-12-08 | — | — | WO | claimed |
| WO-2010151008-A9 | PIPERAZINE DITHIOCTATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CELLTRION CHEMICAL RESEARCH INSTITUTE (KR) | 2011-07-07 | — | — | WO | claimed |
| WO-2010151008-A2 | PIPERAZINE DITHIOCTATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CELLTRION CHEMICAL RESEARCH INSTITUTE (KR) | 2010-12-29 | — | — | WO | claimed |
| CN-119776302-B | Alcohol dehydrogenase mutant and application thereof in synthesizing high-optical-purity (S) -6-hydroxy-8-chlorooctanoic acid ethyl ester | Hangzhou Weiyuan Biotechnology Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-1884234-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CORNEAL AND CONJUNCTIVAL DISORDER | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-5994393-A | Alpha-lipoic acid with novel modification | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096467-A1 | COMBINATION OF SELECTIVE ALPHA-ADRENERGIC RECEPTOR AGONIST OR AN ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF | ADRB2, ADRA2A, ADRB1 | HSD17B10 2221/4885KMT2A 3827/4885TARDBP 3698/4885 |
| US-20120101107-A1 | PIPERAZINE DITHIOCTATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TPMT, TXNDC5, TST | HSD17B10 2308/4885KMT2A 3880/4885TARDBP 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.